Oculis Reports New Phase 2 ACUITY Biomarker Data  Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis

What happened: Oculis Holding AG reported new Phase 2 ACUITY biomarker data showing Privosegtor reduced post-onset increases in plasma NfL and GFAP versus placebo in patients with optic neuritis. Why it matters: The biomarker results support previously reported functional and retinal structural improvements, reinforcing development of Privosegtor for acute optic neuritis and acute multiple sclerosis relapses as Oculis advances the PIONEER registrational program.

Oculis Holding AG reported new Phase 2 ACUITY biomarker data showing Privosegtor reduced post-onset increases in plasma NfL and GFAP versus placebo in patients with optic neuritis.

The biomarker results support previously reported functional and retinal structural improvements, reinforcing development of Privosegtor for acute optic neuritis and acute multiple sclerosis relapses as Oculis advances the PIONEER registrational program.